Since its introduction in 1992, the Brugada syndrome has attracted great interest because of increased risk of sudden cardiac death. Risk stratification aimed at the identification of patients at risk for sudden death is an important goal of current research. Controversy exists on risk stratification particularly in asymptomatic individuals. The predictive value of the inducibility of ventricular tachyarrhythmias is also discussed controversially. Currently, an implantable cardioverter defibrillator is the only proven effective treatment for the disease.